abiraterone acetate

/abiraterone acetate

An Easier, Cheaper and More Comfortable Way To Take Zytiga

Rather than taking – and paying – for the full Zytiga dose on an empty stomach, ask your doctor if you could get the same effect from taking just one fourth of your Zytiga dose while enjoying a low-fat or high-fat breakfast. A small phase two study of 36 prostate cancer patients who took 250 [...]

Ask For a Blood test to identify AR-V7 in Circulating Tumor Cells if you are starting Xtandi or Zytiga

One of the hot topics in the prostate cancer community is the value of detecting AR-V7 tumor cells circulating in the blood. AR-V7 tumor cells in the blood predicts response or failure of treatment with enzalutamide (Xtandi) or abiraterone (Zytiga). A recent study found that men who have AR-V7 circulating tumor cells in their blood will not [...]

Is Alkaline Phosphatase A Bio-Marker To Predict PSA Decline And Clinical Benefit From Abiraterone Acetate in Bone Metastatic Castration Resistant Prostate Cancer

Again and again I have mentioned the huge need we have for the development of reliable bio-markers. Reliable bio-markers will allow us to know which men will respond positively to a treatment (also those who will not) and when a treatment is still effective (also when it no longer is effective). These biomarkers really don’t [...]

Some Factors That Might Be Predictors of the Duration of Abiraterone Acetate in Men with Castration-Resistant Prostate Cancer

Being able to make better decisions about drug sequencing and combinations has become one of the current hot topics in prostate cancer research. Given that we have a number of newer drugs to use this is an important clinical issue as we make important treatment decisions. Making these clinical decisions is tough.  The fact is [...]

Abiraterone And Enzalutamide Effect Cognitive Impairment and Depression in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Speaking with men who have taken abiraterone (Zytiga, ABI) and enzalutamide (Xtandi, ENZA), at Malecare we sometimes hear reports of both cognitive and mood changes brought on by these two drugs. Evaluating these two problematic side effects researchers have confirmed our experience, both of these drugs can cause these symptoms and that more men reported [...]

An Independent Prognostic Tool For Men With Metastatic Castrate Resistant Prostate Cancer Taking The Newer Drugs

We have a number of newer hormone pathway drugs now available to treat men with metastatic castrate resistant prostate cancer (mCRPC). Researchers have shown that prostate specific antigen (PSA) response can be used as a pharmaco-dynamic end-point that may help identify men with early resistance to these new drugs. They found that there is clinical [...]

Real Life Issues About Abiraterone Acetate (Zytiga) Prior to Chemotherapy – Unanticipated Real-World Clinical Experience Worth Noting

Researchers in Hong Kong wanted to confirm the efficacy of abiraterone acetate (Zytiga) used prior to chemotherapy that had been shown in the trial setting. In their analysis they came up short; raising some very significant concerns about Zytiga’s efficacy when used prior to chemotherapy. They reviewed the clinical records of men with metastatic castrate [...]

UK’s NICE Reverses Itself and Now Recommends Zytiga To Treat Men Before Chemotherapy

In a sudden reversal of its prior opinion the UK's National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Janssen’s Zytiga (abiraterone) to treat advanced prostate cancer before chemotherapy. Its prior recommendation was not to approve Zytiga. TAccording to NICE their decision to change their December 2015 recommendation follows the submission [...]

PSA Decline After 4 Weeks of Abiraterone Suggests Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer

Since we have many new treatments for men with castrate resistant metastatic prostate cancer (mCRPC) (advanced prostate cancer) we need to develop earlier indicators of when a treatment might or might not be successful. A decline in prostate-specific antigen (PSA) is widely used to monitor treatment response, but it has not been validated as an [...]

A Small Analysis of Abiraterone Responses in African American Men with Metastatic Castration Resistant Prostate Cancer

Presented at ASCO GU by Stolten and colleagues was abstract 244 that described the responses African American men had to abiraterone (Zytiga) in a retrospective cohort study of men seen at a single institution.  Stolten included differences in the men including their age at diagnosis, prior enzalutamide (Xtandi) and/or docetaxel (chemotherapy) use, as well as [...]